PharmEasy's rollup bet: $5.6B peak, $456M markdown, profitability pivot

PharmEasy's bet was that India's fragmented pharmacy market — millions of small, discount-driven chemists with no digital presence — could be consolidated into one trusted platform. Medicines are a high-frequency, chronically recurring purchase, and the founders believed an app that delivered genuine medicines at better prices, backed by diagnostics and teleconsultation, could become the country's default digital health destination.

Founded in 2015 by Dharmil Sheth and Dr Dhaval Shah, PharmEasy merged with investor entity Ascent Health to form API Holdings in 2019 and became India's first e-pharmacy unicorn in April 2021. It then rolled up the category: rival Medlife, a controlling stake in listed diagnostics chain Thyrocare for ₹4,546 crore, and supply-chain firm Aknamed — all within five months, funded by a $5.6B pre-IPO round and debt.

The debt is where the bet broke. An $843M IPO planned for late 2021 was deferred as markets soured, and a $300M Goldman Sachs loan taken to fund the Thyrocare deal carried covenants the company couldn't meet. A December 2023 rights issue of close to ₹4,000 crore valued the company at about $1B — likely the largest down round in Indian startup history — and by December 2024 investor Janus Henderson's filing implied a valuation of $456M, 92% below the peak.

The company survived by changing what it optimized for. Under CEO Rahul Guha (from August 2025), API Holdings cut monthly losses from ₹50 crore to under ₹2 crore, raised internal procurement from 40% to ~85%, refinanced high-cost debt with ₹1,700 crore NCDs, and targets full-year profitability by March 2027. The pharmacy business it bet on is still there — ~30% of India's online pharmacy market — but the investors who valued it at $5.6B are still waiting for their money back.